Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Contact allergy in cheilitis
O’Gorman, Susan M., Torgerson, Rochelle R.

International Journal of Dermatology | November 8, 2015 | Volume: 55 | Issue: 7 | Pages: No page available

10.1111/ijd.13044 | PMID 26547761 Get It

Abstract Background Recalcitrant non‐actinic cheilitis may indicate contact allergy. Objectives This study aimed to determine the prevalence of allergic contact cheilitis (ACC) in patients with non‐actinic cheilitis and to identify the most relevant allergens. Methods We used an institutional database to identify patients with non‐actinic cheilitis who underwent patch testing between January 1, 2001, and August 31, 2011, and conducted a retrospective review of patch test results in these patients. Additional data were obtained from institutional electronic medical records. Results Ninety‐one patients (70 [77%] female; mean age: 51 years) were included in the study. Almost half (41 [45%]) had a final diagnosis of ACC. Patch testing was performed in line with universally accepted methods, with application on day 1, allergen removal and an initial reading on day 3, and the final reading on day 5. The allergens of most significance were fragrance mix, Myroxylon pereirae resin, dodecyl gallate, octyl gallate, and benzoic acid. Nickel was the most relevant metal allergen. Conclusions Contact allergy is an important consideration in recalcitrant cheilitis. Fragrances, antioxidants, and preservatives dominated the list of relevant allergens in our patients. Nickel and gold were among the top 10 allergens. Almost half (45%) of these patients had a final diagnosis of ACC. Patch testing beyond the oral complete series should be undertaken in any investigation of non‐actinic cheilitis.
Predicting the Overuse of PCSK-9 Inhibitors
Rodríguez‐Gutiérrez, René , Shah, Nilay D. , Montori, Víctor M. , Montori, Victor M

JAMA | November 8, 2015 | Volume: 314 | Issue: 18 | Pages: 1909

10.1001/jama.2015.13414 | PMID 26547456 Get It

Electrophoretic Mobility of Leukocyte Elastase of Normal Subjects and Patients With Chronic Obstructive Pulmonary Disease
Taylor, Joseph C., Kueppers, Friedrich

American Review of Respiratory Disease | November 7, 2015 | Volume: 116 | Issue: 3 | Pages: 531-536

10.1164/arrd.1977.116.3.531 | PMID 409318 Get It

Abstract The granulocyte lysosomal elastase of 17 patients with chronic obstructive pulmonary disease and of 27 normal subjects was examined. Serum a 1-antitrypsin phenotypes were identical in the 2 groups: 88 per cent were type PiM and 12 per cent were type PiMS. Electrophoresis of granulocyte lysosomal extracts at pH 8.6 revealed interindividual differences in the electrophoretic mobility of the elastase enzyme. The elastases clustered into 3 regions of electrophoretic mobility, which we designated as fast (>29 mm), intermediate (24 through 29 mm), and slow (<24 mm) migration. A comparison of the number of patients and normal subjects in each electrophoretic category showed an almost 4-fold increase in the prevalence of the slow electrophoretic type of elastase in the patient group compared to the normal subjects. Esterase activity in lysosomal extracts against the synthetic elastase substrate N-t-BOC-L-alanine-p-nitrophenyl ester (NBA) varied within a 4 to 5-fold range in both patient and normal populations. No significant differences in the mean esterase activities between the patient group and the normal group could be detected within each elastase category (slow, intermediate, or fast mobility). The mean elastase NBA esterase activity was lowest in the slow elastase electrophoretic category and highest in the fast elastase type. Mean esterase activity in the intermediate electrophoretic category was intermediate between those of the slow and the fast electrophoretic types of elastase. The increase in the number of patients in the slow electrophoretic category with lowest mean elastase esterase activity suggests that qualitative rather than quantitative aspects of elastase may be critical in the pathogenesis of chronic obstructive pulmonary disease in patients with normal a 1-antitrypsin phenotypes.
Early Diagnosis of Lung Cancer
Fontana, Robert S.

American Review of Respiratory Disease | November 7, 2015 | Volume: 116 | Issue: 3 | Pages: 399-402

10.1164/arrd.1977.116.3.399 | PMID 900629 Get It

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, Jasvinder A. , Bridges, S. Louis , Bannuru, Raveendhara R. , Sullivan, Matthew C. , Vaysbrot, Elizaveta E., McNaughton, Christine, Osani, Mikala C. , Parks, Deborah, Kavanaugh, Arthur, O’Dell, James R., Leong, Amye , Matteson, Eric L. , Drevlow, Barbara E., Ginsberg, Seth, Grober, James, Clair, E. William St. , Tindall, Elizabeth A., Miller, Amy S., Saag, Kenneth G. , Akl, Elie A. , Shmerling, Robert H. , Curtis, Jeffrey R. , Furst, Daniel E. , King, Charles M. , Schousboe, John T. , Grober, James, McAlindon, Timothy E. , Singh, Jasvinder A , Bannuru, Raveendhara R

Arthritis Care & Research | November 6, 2015 | Volume: 68 | Issue: 1 | Pages: 1-25

10.1002/acr.22783 | PMID 26545825 Get It

ObjectiveTo develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA).MethodsWe conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences.ResultsThe guideline covers the use of traditional disease‐modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat‐to‐target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional.ConclusionThis RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision‐making process taking into account patients’ values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
When Patients Write the Guidelines: Patient Panel Recommendations for the Treatment of Rheumatoid Arthritis
Miller, Amy S., Clayton, K., Crow‐Hercher, Rachelle, Hazel, Shantana, Rott, Leslie M., White, Whitney, Wiedmeyer, Carole, Montori, Víctor M. , Singh, Jasvinder A. , Nowell, W. Benjamin , Fraenkel, Liana , Johnson, Britt , Singh, Jasvinder A , Montori, Victor M

Arthritis Care & Research | November 6, 2015 | Volume: 68 | Issue: 1 | Pages: 26-35

10.1002/acr.22758 | PMID 26545701 Get It

ObjectiveHow best to involve patients in the development of clinical practice guideline (CPG) recommendations is not known. We sought to determine the feasibility and value of developing CPG recommendations based on a voting panel composed entirely of patients, with the ultimate goal of comparing the patients’ recommendations to ones developed by a physician‐dominated voting panel on the same clinical questions.MethodsTen patients with rheumatoid arthritis completed 8 hours of training on evidence‐based medicine and guideline development. They constituted a voting panel and, with 2 American College of Rheumatology staff with expertise in CPG development and a physician facilitator, subsequently met at a face‐to‐face meeting to develop recommendations. They applied the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology to formulate recommendations on 18 questions for which there was evidence warranting moderate or high confidence.ResultsThe patient panel developed recommendations for 16 of the 18 questions; for the other 2, the panel thought there were insufficient data to support a recommendation. For 13 of the 16 questions, the patient panel recommended the same course of action as did the physician‐dominated panel. Differences were due to how the 2 panels valued the balance between benefits and harms.ConclusionPatient and physician‐dominated panels developed the same recommendations for most questions for which there was evidence warranting moderate to high confidence. Additional experiences are necessary to advance the evidence necessary to determine what panel composition is optimal to produce the best guidelines.
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, Jasvinder A. , Bridges, S. Louis , Bannuru, Raveendhara R. , Sullivan, Matthew C. , Vaysbrot, Elizaveta E., McNaughton, Christine, Osani, Mikala C. , Parks, Deborah, Kavanaugh, Arthur, O’Dell, James R., Leong, Amye , Matteson, Eric L. , Drevlow, Barbara E., Ginsberg, Seth, Grober, James, Clair, E. William St. , Tindall, Elizabeth A., Miller, Amy S., McAlindon, Timothy E. , Saag, Kenneth G. , Akl, Elie A. , Shmerling, Robert H. , Curtis, Jeffrey R. , Furst, Daniel E. , King, Charles M. , Schousboe, John T. , Grober, James, Singh, Jasvinder A , Bannuru, Raveendhara R

Arthritis & Rheumatology | November 6, 2015 | Volume: 68 | Issue: 1 | Pages: 1-26

10.1002/art.39480 | PMID 26545940 Get It

Objective To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences. Results The guideline covers the use of traditional disease‐modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat‐to‐target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional. Conclusion This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision‐making process taking into account patients’ values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
A randomized trial comparing multiband mucosectomy and cap-assisted endoscopic resection for endoscopic piecemeal resection of early squamous neoplasia of the esophagus
Zhang, Yue-Ming, Boerwinkel, David F., Qin, Xiumin, He, Shun , Xue, Liyan , Weusten, Bas L. , Fleischer, David E., Dou, Lizhou, Lü, Ning , Bergman, Jacques , Wang, Gui-Qi, Dawsey, Sanford M. , Liu, Yong

Endoscopy | November 6, 2015 | Volume: 48 | Issue: 04 | Pages: 330-338

10.1055/s-0034-1393358 | PMID 26545174 Get It

Liver transplantation in the management of perihilar cholangiocarcinoma
Gulamhusein, Aliya , Gulamhusein, Aliya F, Sánchez, William

Hepatic Oncology | November 6, 2015 | Volume: 2 | Issue: 4 | Pages: 409-421

10.2217/hep.15.30 | PMID 30191020 Get It

Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis
Benkhadra, Khalid, Mohammed, Khaled , Nofal, Alaa Al , Leon, Barbara Gisella Carranza, Alahdab, Fares , Montori, Víctor M. , Dabrh, Abd Moain Abu , Zuñiga-Hernández, Jorge A , Murad, M. Hassan , Al Nofal, Alaa, Carranza Leon, Barbara G, Faubion, Stephanie, Abu Dabrh, Abd Moain, Zúñiga Hernández, Jorge Alberto, Murad, Mohammad Hassan, Faubion, Stephanie S. , Prokop, Larry J. , Murad, M Hassan , Al Nofal, Alaa , Zuñiga-Hernandez, Jorge Alberto , Montori, Victor M , Abu Dabrh, Abd Moain , Alahdab, Fares

The Journal of Clinical Endocrinology & Metabolism | November 6, 2015 | Volume: 100 | Issue: 11 | Pages: 4021-4028

10.1210/jc.2015-2238 | PMID 26544652 Get It

Objectives: The objective was to assess the effect of menopausal hormonal therapy (MHT) on all-cause and cause-specific mortality. Methods: We conducted a comprehensive search of several databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, and Scopus) from inception until August 2013. We included randomized controlled trials (RCTs) of more than 6 months of duration comparing MHT with no treatment. Pairs of independent reviewers selected trials, assessed risk of bias and extracted data. We estimated risk ratios (RRs) and 95% confidence intervals (CIs) using the random-effects model. Results: We included 43 RCTs at moderate risk of bias. Meta-analysis showed no effect on mortality (RR 0.99 [95% CI, 0.94–1.05]), regardless of MHT type or history of preexisting heart disease. No association was found between MHT and cardiac death (RR 1.04 [95% CI 0.87–1.23]) or stroke (RR 1.49 [95% CI 0.95–2.31]). Estrogen plus progesterone use was associated with a likely increase in breast cancer mortality (RR 1.96 [95% CI 0.98–3.94]), whereas estrogen use was not. MHT use was not associated with mortality of other types of cancer. In 5 trials, MHT was likely started at a younger age: 2 RCTs with mean age less than 60 and 3 RCTs with MHT started less than 10 years after menopause. Meta-analysis of these 5 RCTs showed a reduction of mortality with MHT (RR 0.70 [95% CI 0.52–0.95]). Conclusion: The current evidence suggests that MHT does not affect the risk of death from all causes, cardiac death and death from stroke or cancer. These data may be used to support clinical and policy deliberations about the role of MHT in the care of symptomatic postmenopausal women.